Cause-specific mortality adjudication in the UPLIFT® COPD trial: Findings and recommendations

References

Page 1

	Year	Citations
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease Donald P. Tashkin, Bartolomé R. Celli, Stephen Senn, New England Journal of Medicine	2008	2.2K
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study Nicholas R. Anthonisen JAMA Tobacco CessationAsthmaPulmonary CareAdvanced Lung DiseaseLung Inflammation	1994	1.6K
Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 Nicholas R. Anthonisen JAMA AsthmaTobacco CessationPulmonary CareAdvanced Lung DiseaseNicotine Gum	1994	1.3K
Fish Consumption and Risk of Sudden Cardiac Death Christine M. Albert JAMA	1998	988
Hospitalizations and Mortality in the Lung Health Study Nicholas R. Anthonisen, John E. Connett, Paul Enright, American Journal of Respiratory and Critical Care Medicine AsthmaHeart FailurePulmonary CareAdvanced Lung DiseasePharmacotherapy	2002	588
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee Lorcan McGarvey, M. Knight John, J. Anderson, Thorax	2007	549
Prediction of Mode of Death in Heart Failure Dariush Mozaffarian, Stefan D. Anker, Inder S. Anand, Circulation	2007	302
Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease Bartolomé R. Celli, Marc Decramer, Steven Kesten, American Journal of Respiratory and Critical Care Medicine	2009	284
COPD is associated with increased mortality in patients with community-acquired pneumonia Marcos I. Restrepo, Eric M. Mortensen, Jacqueline A. Pugh, European Respiratory Journal AsthmaCommunity-acquired PneumoniaEpidemiologyAdvanced Lung DiseaseIncreased Mortality	2006	263
Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients Scott D. Solomon, Duolao Wang, Peter Finn, Circulation	2004	258

Page 1